Scientists at Oxford University are accelerating the development of a novel vaccine targeting the Bundibugyo species of the Ebola virus, with the goal of reaching clinical trials within the next two to three months. This rare strain, which has historically caused significant mortality, currently lacks any approved preventative treatment. The research team is utilizing the ChAdOx1 platform—the same technology successfully deployed during the Covid-19 pandemic—to engineer a vaccine that trains the immune system to recognize and neutralize the virus without causing infection.

The urgency of this project follows a surge in cases within the Democratic Republic of Congo, where health authorities have elevated the risk level to “very high.” While current containment strategies rely on contact tracing and quarantine, the potential for the outbreak to escalate has prompted researchers to prepare for a worst-case scenario. The vaccine candidate uses a modified chimpanzee cold virus to deliver genetic instructions to human cells, a method proven to be highly adaptable for rapid response to emerging pathogens.

Animal testing is currently underway to determine the efficacy of the candidate, a critical step before human trials can commence. To ensure scalability, the Serum Institute of India has been identified as a partner for mass production should the vaccine prove successful. Unlike mass-immunization campaigns, any future deployment of this vaccine would likely follow a “ring vaccination” strategy, focusing on healthcare workers and individuals in direct contact with infected patients to break the chain of transmission.